Scotland is world’s first country to greenlight Tagrisso for NSCLCScotland has given the green light to AstraZeneca’s Tagrisso for restricted use to treat adult patients with non-small Share XScotland is world’s first country to greenlight Tagrisso for NSCLChttps://pharmaphorum.com/news/scotland-is-worlds-first-country-to-greenlight-tagrisso-for-nsclc/
Roche scores adjuvant lung cancer approval for TecentriqRoche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), Share XRoche scores adjuvant lung cancer approval for Tecentriqhttps://pharmaphorum.com/news/roche-scores-early-adjuvant-lung-cancer-approval-for-tecentriq/
ESMO21: Libtayo extends survival in first-line NSCLC, challenging KeytrudaThere’s no shortage of cancer immunotherapies trying to knock Merck & Co’s Keytruda off the top of the Share XESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytrudahttps://pharmaphorum.com/news/esmo21-libtayo-extends-survival-in-first-line-nsclc-challenging-keytruda/
Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approvalTakeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late, Share XTakeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approvalhttps://pharmaphorum.com/news/takeda-gets-a-win-for-its-wave1-pipeline-as-exkivity-nabs-fda-approval/
Merck’s targeted lung cancer drug tepotinib wins early access in UKThe UK drugs regulator has backed Merck KGaA’s MET inhibitor for the treatment of some patients with non-small Share XMerck’s targeted lung cancer drug tepotinib wins early access in UKhttps://pharmaphorum.com/news/mercks-targeted-lung-cancer-drug-tepotinib-wins-early-access-in-uk/
Amgen nabs speedy approval for first-ever KRAS drug sotorasibAfter decades of mostly unsuccessful R&D, Amgen has claimed the first ever regulatory approval for a drug that Share XAmgen nabs speedy approval for first-ever KRAS drug sotorasibhttps://pharmaphorum.com/news/amgen-nabs-speedy-approval-for-first-ever-kras-drug-sotorasib/
Janssen claims FDA okay for would-be Tagrisso rival RybrevantJohnson & Johnson’s Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant Share XJanssen claims FDA okay for would-be Tagrisso rival Rybrevanthttps://pharmaphorum.com/news/janssen-claims-swift-fda-okay-for-precision-cancer-drug-rybrevant/
Tagrisso trial halted early after ‘overwhelming’ efficacyA phase III trial for AstraZeneca’s lung cancer drug Tagrisso (osimertinib) will be unblinded early after strong results. Share XTagrisso trial halted early after ‘overwhelming’ efficacyhttps://pharmaphorum.com/news/tagrisso-trial-halted-early-after-overwhelming-efficacy/
Keytruda approved for combination lung cancer therapyThe US Food and Drug Administration (FDA) has approved Merck & Co’s Keytruda plus chemotherapy as a first-line Share XKeytruda approved for combination lung cancer therapyhttps://pharmaphorum.com/news/keytruda-approved-for-combination-lung-cancer-therapy/
